Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under...

Pharvaris Announces Phase 1 Clinical Data of PHA121, an Oral B2 Receptor Antagonist Under Developmen

t for the Treatment of Hereditary Angioedema

"Data demonstrate the oral bioavailability of PHA121, which was well-tolerated across multiple ascending doses..."

012821 Pharvaris Announces Phase 1 Clini

.

Download • 54KB